An outbreak aboard the MV Hondius has been associated with several severe cases and international action; experts say public risk is low but awareness is essential
The recent cluster of severe respiratory illness on board the Dutch-flagged cruise ship MV Hondius has drawn attention from public-health authorities. Initial notifications were sent to the World Health Organization (WHO) on 2 May 2026, and by 4 May 2026 several cases had been identified and investigated.
Media reporting on 8 May 2026 noted an expanded count of cases, including reports that three British nationals were among those affected. Overall event reports indicate multiple fatalities and several confirmed or suspected infections associated with hantavirus, prompting coordinated international response measures.
The vessel followed an itinerary from Ushuaia, Argentina, visiting remote sites such as mainland Antarctica, South Georgia, and islands including Tristan da Cunha, Saint Helena and Ascension. Passengers and crew span numerous nationalities. Medical evacuations, case isolation and laboratory testing have been carried out in several countries, with the National Institute for Communicable Diseases (NICD) of South Africa confirming at least one case by PCR on 2 May 2026.
WHO has described the situation as under active investigation and continues to assess public risk.
Clinical picture and what to watch for
Illness associated with these cases has typically begun with non-specific symptoms such as fever, myalgia and gastrointestinal upset, and in some people progressed rapidly to severe respiratory compromise. Health agencies describe the advanced disease as Hantavirus pulmonary syndrome (HPS) or Hantavirus cardiopulmonary syndrome (HCPS). For clarity, HPS refers to the severe respiratory manifestation that may include cough, shortness of breath, rapid onset of pulmonary oedema and shock. Symptoms commonly reported in the cluster include fever, headache, nausea, abdominal pain and a swift deterioration to pneumonia and acute respiratory distress in some cases.
Incubation and severity
According to public-health guidance, the time from exposure to symptom onset can vary. Typical onset occurs within two to four weeks, although reports indicate it may appear as early as one week or as late as eight weeks after exposure. Severity varies by viral species and region; case fatality rates differ widely worldwide. There is no proven antiviral or specific vaccine for most hantaviruses, so early supportive care in an intensive care setting remains the cornerstone of management for severe cases.
Transmission pathways and precautions
The primary source of human infection is contact with infected rodents or their excreta. In practical terms, transmission most often occurs when people inhale aerosolised particles contaminated with rodent urine, faeces or saliva, or when they touch contaminated surfaces and then touch their mouth or nose. Importantly, a specific species known as Andes virus has previously demonstrated rare instances of limited human-to-human transmission, typically after prolonged close contact. This possibility has influenced the cautious approach taken by authorities in the current event.
On-board and traveller hygiene measures
WHO and national teams recommend practical measures for passengers and crew: practice frequent hand hygiene, avoid activities that resuspend dust (for example, avoid dry sweeping), ensure adequate ventilation and maintain enhanced environmental cleaning. People with respiratory symptoms should self-isolate where possible, wear a medical mask if coughing, and notify ship medical staff immediately. Crew involved in sanitation should follow protective protocols to reduce exposure to potential rodent contamination.
Public-health response and testing
Countries involved — including Cabo Verde, the Netherlands, Spain, South Africa and the United Kingdom — established coordinated actions such as contact tracing, medical evacuation, clinical care support and laboratory confirmation. Confirmatory testing for hantavirus involves molecular assays such as RT–PCR to detect viral RNA and serologic assays like ELISA to identify specific antibodies. Ongoing sequencing and metagenomics work aim to characterise the causative strain and clarify transmission chains.
WHO currently considers the risk to the global population as low, while urging vigilance. Passengers and crew are advised to monitor themselves for symptoms for a period of 45 days, and healthcare facilities should apply standard and transmission-based precautions when managing suspected cases. Prompt recognition, early isolation and escalation of care to an intensive care facility when needed are critical to improving outcomes.
In summary, this cruise-related cluster has triggered multi-country investigation and targeted public-health interventions. Although the situation is serious for those affected, authorities emphasise that the wider public risk remains limited. Travellers, seafaring staff and communities connected to the voyage should remain informed, follow the recommended hygiene and isolation measures, and seek medical attention promptly if symptoms develop.
